Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Legence Q4 2025 Earnings Call - Record revenue and backlog driven by data center fabrication and Bowers acquisition
Legence closed 2025 with a blowout quarter, reporting Q4 revenue of $738 million, up 35% year over year, and record backlog and awards of $3.7 billion, up nearly 50% year over year. Management says mo...
- Q4 2025 revenue $738 million, up 35% year over year, quarter was well ahead of prior guidance.
- Full year 2025 revenue $2.6 billion, up 22%; adjusted EBITDA for FY2025 $299 million, up 30% year over year.
- Q4 adjusted EBITDA $87 million, up 53% year over year; adjusted EBITDA margin improved ~140 basis points to 11.8% in the quarter.
- +16 more takeaways
Southland Q4 2025 Earnings Call - Sureties step in after $136M Washington State Convention Center charge
Southland reported a brutal Q4 and full-year 2025, with revenue for the quarter of $104 million and a $193 million gross loss driven by legacy-project writedowns. The headline charge was a $136 millio...
- Q4 revenue was $104 million, but that figure includes a $92 million revenue reversal tied to legacy dispute adjustments.
- Reported Q4 gross loss was $193 million, sharply worse than prior year Q4 gross profit of $8 million.
- A $136 million adverse trial ruling on the Washington State Convention Center (WSCC) project was the primary driver of the charge, including an $85 million judgment, $40 million reversal of an expected recovery, $6.4 million retention, and $4.8 million related to a sanctions order as described by management.
- +11 more takeaways
Autolus Therapeutics Q4 2025 Earnings Call - Strong first-year AUCATZYL sales ($74M) validate launch but scaling, margins and cash runway become the next test
Autolus closed 2025 with a credible first commercial year for AUCATZYL, recognizing $74.3 million in net product revenue and activating 67 treatment centers. Management reiterated 2026 guidance of $12...
- AUCATZYL first full year revenue in 2025 was $74.3 million, with Q4 product revenue of $23.3 million and total Q4 revenue $24.3 million including a $1 million Moderna milestone.
- Company reiterates 2026 net revenue guidance of $120 million to $135 million and targets more than 80 activated centers by year-end 2026, up from 67 at end-2025.
- Autolus expects to shift to positive gross margins in 2026, driven by higher volumes that spread fixed costs and by operational improvements to lower variable cost per batch.
- +11 more takeaways
Sanuwave Q4 2025 Earnings Call - Record Quarter Despite CMS Audit Shock, Pivot to Resellers
Sanuwave closed 2025 on a high note, posting record Q4 revenue and system placements even as a brutal CMS reset on skin substitutes rippled through the wound-care ecosystem. Management says UltraMIST ...
- Q4 2025 revenue hit an all-time quarterly high of $13.4 million, up 30% year over year, and adjusted EBITDA was $4.8 million, representing 36% of revenue.
- Full-year 2025 revenue was $44.1 million, a 35% increase versus 2024, and full-year adjusted EBITDA rose 89% to $13.6 million from $7.2 million.
- System placements accelerated, with 624 UltraMIST systems sold in 2025 versus 374 in 2024, and Q4 2025 alone accounted for a record 255 system sales.
- +13 more takeaways
Kopin Corporation Fourth Quarter 2025 Earnings Call - Government shutdown dents Q4, $56M capital and MicroLED pipeline position Kopin for a 2026 rebound
Kopin framed Q4 2025 as a hiccup, not a trend. Revenues plunged to $8.4 million from $14.6 million the prior year, with management attributing the shortfall to deeper-than-expected procurement delays ...
- Q4 2025 revenue fell to $8.4 million, down from $14.6 million in Q4 2024, management attributes the decline mainly to procurement and milestone recognition delays from the U.S. government shutdown.
- Kopin completed a $56 million private placement in 2025, which management says removed going concern doubt and materially strengthened the balance sheet.
- Year-end backlog was reported around $37 million, and management expects to book additional tens-of-millions of dollars in orders within the next 6 to 8 weeks.
- +12 more takeaways
SBC Medical Group Holdings Q4 FY2025 Earnings Call - Profitability Normalizes After Restructuring; AI and Longevity Become Growth Playbooks
SBC reported a messy but familiar reset. Clinic-level metrics show early signs of recovery, led by a sharp Q4 rebound in average revenue per customer to $316, while consolidated revenue fell as the co...
- Clinic footprint and customer base: SBC operates 283 locations and served 6.63 million customers on a trailing twelve month basis as of December 2025.
- Clinic revenue vs consolidated revenue: Company reported total clinic revenue of $1,163 million for the year, a 2% increase year over year, while consolidated full year revenue was stated as $174 million, down 15% year over year due to 2024 restructuring and April 2025 fee changes, suggesting different scopes or reporting layers that need clarification.
- Q4 unit economics rebound: Average revenue per customer reversed prior declines and rebounded to $316 in Q4, an 11% year-over-year increase, which management called an inflection in underlying momentum.
- +11 more takeaways
Super League Gaming Q4 2025 Earnings Call - Misfits Ads deal positioned as the fast track to cash EBITDA by year-end 2026
Super League says 2025 was a reset year, and the numbers show a company that has cut costs, cleaned its balance sheet, and is now trying to buy its way to scale. Management reported its strongest reve...
- Company says Q4 2025 was the strongest revenue quarter of the year, revenue up 32% versus Q3 2025 and roughly level with Q4 2024.
- Super League ended 2025 debt-free, with more than $14 million in capital as of December 31, and removal of the going-concern language from the auditor’s report.
- Management reports full-year gross margin improved to 40% in 2025 from 38% in 2024, and believes sustainable gross margin sits in the 40%–45% range.
- +11 more takeaways
The Metals Company Q4 2025 Earnings Call - U.S. permitting momentum fuels Brownsville processing push and Hidden Gem commissioning timeline
The Metals Company used this update to push a single narrative, regulatory clarity equals commercial runway. Management flagged a strategic pivot to the U.S. Deep Seabed Hard Mineral Resources Act, a ...
- Company pivoted from ISA to U.S. regulatory regime under the Deep Seabed Hard Mineral Resources Act (DSHMRA) and President Trump�s executive order, positioning the U.S. as the primary jurisdiction for its development.
- TMC submitted the first consolidated NOAA application under the revised permitting process, which was deemed substantially compliant; management expects grant of the commercial recovery permit within 12 months.
- Consolidated application expands expected commercial recovery area from 25,000 sq km to approximately 65,000 sq km.
- +16 more takeaways
Nortech Systems Incorporated Q4 2025 Earnings Call - Restructuring Drives Margin Recovery and Backlog Jump
Nortech closed 2025 with operational momentum driven by restructuring and plant transfers, producing the third consecutive quarter of positive operating and EBITDA results and a marked improvement in ...
- Restructuring payoff, third straight quarter of positive operating and EBITDA results, management credited $2.1 million improvement in income from operations in Q4 2025 versus Q4 2024.
- Backlog rose to $77.3 million at year-end 2025, up 17.4% from $65.9 million, and management says backlog gains continued into Q1 2026.
- Annual net sales fell to $118.4 million in 2025, a 7.6% decline from $128.1 million in 2024, reflecting customer inventory rebalancing, program timing, and industrial demand softness.
- +12 more takeaways
Humacyte Fourth Quarter 2025 Earnings Call - Symvess commercialization gains traction with DoD funding, Saudi commitment, and dialysis interim readout due June 2026
Humacyte closed 2025 with early commercial traction for Symvess, a clear push into international markets, and an accelerated clinical calendar for its dialysis and coronary programs. The company repor...
- Symvess commercial rollout shows early traction: 27 VAC approvals in the U.S., ~43 VAC committees still under review, and 27 hospitals have ordered product with most placing reorders.
- Revenue and unit sales remain small but real: Q4 product sales $0.4 million (25 units), 2025 product sales $1.4 million (61 units), total 2025 revenue $2.0 million including a research collaboration.
- Price reset to $17,000 drove improved VAC success and shelf conversion, with management saying VAC approval success rate is roughly 70% after the price change.
- +12 more takeaways